LUND, Sweden, Aug. 28, 2020 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia"), today announced that the company will be
hosting the second webinar in the series on Immunovia's IMMray™
PanCan-d. This second webinar will cover the results of the
Commercial Test Model Study (link to pr) and updates on the launch
activities.
Event Details:
Immunovia's IMMray™ PanCan-d Webinar Series
Webinar No. 2: Commercial Test Model Study & Update
on Launch Activities
Date and Time: September 2,
2020 at 16:00 CET
Presenters: Linda Mellby, PhD; Thomas King, MD, PhD, and Laura Chirica, PhD
Immediately after the webinar, the Immunovia team will host a
live Q&A session.
To join the Webinar: Register for Webinar
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/registration-details-for-immunovia-s-second-webinar-in-the-series-on-immray--pancan-d--commercial-te,c3183172
The following files are available for download:
|
https://mb.cision.com/Main/13121/3183172/1298846.pdf
|
Release
|